MedTrace Logo

Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)

NCT07777445 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-20

No results posted yet for this study

Summary

The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).

Conditions

  • Pulmonary Vascular Disease
  • Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  • Pulmonary Arterial Hypertension (PAH)

Interventions

OTHER

6-minute walk distance (6MWD) test on ambient conditions

6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards

OTHER

6-minute walk distance (6MWD) test with supplemental oxygen (LOX)

6-minute walk test(6MWT) test will be performed according to clinical standards with supplemental liquid oxygen therapy (LOX, approximately 4l/min, nasal)

Sponsors & Collaborators

  • Silvia Ulrich Somaini

    lead OTHER

Principal Investigators

  • Silvia Ulrich, Prof. Dr. med. · University Hospital Zurich, Department of Pulmonology

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07777445 on ClinicalTrials.gov